Report : Europe Lyophilized Injectable Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type of Packaging (Single-Use Vials, Point-of-Care Reconstitution, and Specialty Packaging), Type of Delivery (Prefilled Diluent Syringes, Single-Step Devices, Proprietary Reconstitution Devices, and Multi-Step Devices), Indication (Metabolic and Oncology Conditions, Infectious Diseases, Autoimmune Diseases, and Others), and End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others)
At 5.4% CAGR, the Europe Lyophilized Injectable Market is speculated to be worth US$ 1,108.45 million by 2028, says Business Market Insights
According to Business Market Insights' research, the Europe lyophilized injectable market was valued at US$ 808.34 million in 2022 and is expected to reach US$ 1,108.45 million by 2028, registering a CAGR of 5.4% from 2022 to 2028. Increasing demand of biologics and increasing demand for contract research manufacturing services are the critical factors attributed to the market expansion.
The supply of numerous biologics in a liquid form is not possible. Pharmaceutical organizations may also have concerns that the pharmacodynamic and pharmacokinetic properties of certain biologics in a liquid stable format may lessen over time. For biologics and other drugs, their supply is done in a lyophilized or powder form requiring reconstitution at the point of delivery, which is the only feasible pathway for the product's commercial launch. A significant boom has been witnessed in the contract manufacturing of biologics. This can be attributed to difficulties in the production of large-scale biologics in-house. There is a need to scale up the production once novel technologies get approved-for instance, manufacturing of CAR-T therapy. With more biological products and biosimilars entering the market, the competition within the biopharmaceutical sector is becoming fierce. Biologics manufacturers strive to reduce manufacturing cost, deliver high-quality drugs, improve process efficiency, and accelerate market entry. CMOs can adopt as per requirement and help in process innovation and improve operational efficiency. As the pharmaceutical industry is shifting from large-scale production to more niche and targeted therapies (personalized medicine), the demand of flexible operational capabilities, production scales, and multiple-product operations are offering significant advantages to CMOs. Moreover, many companies are opting CMOs services to speed up the development process and lower production costs. Thus, the importance of lyophilization in the successful delivery of biologics boosts the use of lyophilized injectables, thereby driving the market growth across the region.
On the contrary, growing rate of product recalls hurdles the growth of Europe lyophilized injectable market.
Based on type of packaging, the Europe lyophilized injectable market is segmented into single-use vials, point-of-care reconstitution, and specialty packaging. The single-use vials segment held 48.1% market share in 2022, amassing US$ 388.49 million. It is projected to garner US$ 528.23 million by 2028 to expand at 5.3% CAGR during 2022-2028.
Based on type of delivery, the Europe lyophilized injectable market is segmented into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held 44.0% market share in 2022, amassing US$ 355.82 million. It is projected to garner US$ 501.71 million by 2028 to expand at 5.9% CAGR during 2022-2028.
Based on indication, the Europe lyophilized injectable market is segmented into metabolic and oncology conditions, infectious diseases, autoimmune diseases, and others. The metabolic and oncology conditions segment held 46.3% market share in 2022, amassing US$ 374.61 million. It is projected to garner US$ 524.71 million by 2028 to expand at 5.8% CAGR during 2022-2028.
Based on end user, the Europe lyophilized injectable market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment held 47.6% market share in 2022, amassing US$ 384.91 million. It is projected to garner US$ 532.01 million by 2028 to expand at 5.5% CAGR during 2022-2028.
Based on country, the Europe lyophilized injectable market has been categorized into the UK, Germany, France, Italy, Spain, and the rest of Europe. Our regional analysis states that Germany captured 26.8% market share in 2022. It was assessed at US$ 216.64 million in 2022 and is likely to hit US$ 314.02 million by 2028, exhibiting a CAGR of 6.4% during the forecast period.
Key players dominating the Europe lyophilized injectable market are Aristopharma Ltd.; Baxter; CordenPharma International; Credence MedSystems, Inc.; Curia Global, Inc.; Jubilant HollisterStier (Jubilant Pharma Limited); Nipro; Recipharm AB; S.G. Biopharm Pvt. Ltd.; and Vetter Pharma among others.
In March 2021, Baxter International Inc. and Moderna, Inc. announced that they have entered into an agreement for Baxter BioPharma Solutions to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021.
In Oct 2020, Credence MedSystems and SCHOTT AG have formed a collaboration for the application of Credence Companion technology with SCHOTT's pre-fillable syriQ glass and SCHOTT TOPPAC polymer syringe systems. The two companies will work together to integrate the technologies and provide the pharmaceutical industry with an innovative and differentiated offering for the delivery of injectable medications via prefilled syringes.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com